Key result
AHA PREVENT equations estimate 10-year and lifetime ASCVD and HF risk without race-based variables.
Why the study?
Rising prevalence of metabolic risk factors and chronic kidney disease alongside shifts in risk factor contributions have caused previous equations like the Pooled Cohort Equations to overestimate 10-year ASCVD risk, necessitating new constructs for cardiometabolic risk stratification.
The AHA PREVENT equations provide a comprehensive, non-race-based tool incorporating kidney and metabolic health to estimate 10-year and lifetime risk of both ASCVD and heart failure starting at age 30.
PREVENT equations enable earlier, inclusive CKM risk estimation from age 30; leaves open whether adoption improves outcomes versus PCEs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Garba et al. (2024) conducted a review in Cardiovascular-kidney-metabolic (CKM) syndrome and cardiovascular disease risk. PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) equations vs. Pooled Cohort Equations (PCEs) and Framingham risk equations was evaluated on Composite of atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF). The AHA PREVENT equations estimate 10-year and lifelong risk of ASCVD and heart failure in adults aged 30-79 using non-race-based cardiovascular, kidney, and metabolic variables.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: